Second, increased SHP2 phosphorylation is observed in breast cancer cells resistant to the HER2 TKI neratinib, where it acts as a shared signaling node that integrates inputs from the extracellular matrix and receptor tyrosine kinases (RTKs), thereby promoting drug resistance and metastasis (Chen et al., 2020). Here, PTPN11 is linked to breast carcinoma.